Arrowhead Research Corp (ARWR) : University Of Texas Investment Managment Co has sold out all of its stake in Arrowhead Research Corp during the most recent quarter, according to the disclosure filed by the company on Aug 11, 2016 with the SEC. The investment management company has sold out 35,817 shares of Arrowhead Research Corp which is valued at $213,469.
Other Hedge Funds, Including , Teachers Advisors Inc reduced its stake in ARWR by selling 132 shares or 0.15% in the most recent quarter. The Hedge Fund company now holds 90,356 shares of ARWR which is valued at $538,522. Financial Architects Inc added ARWR to its portfolio by purchasing 4,000 company shares during the most recent quarter which is valued at $24,040. Arrowhead Research Corp makes up approx 0.01% of Financial Architects Inc’s portfolio.
Arrowhead Research Corp opened for trading at $7.83 and hit $8.22 on the upside on Tuesday, eventually ending the session at $8.08, with a gain of 4.26% or 0.33 points. The heightened volatility saw the trading volume jump to 15,90,232 shares. Company has a market cap of $491 M.
On the company’s financial health, Arrowhead Research Corp reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The company’s revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on Arrowhead Research Corp. Cantor Fitzgerald Initiated Arrowhead Research Corp on Aug 18, 2016 to “Buy”, Price Target of the shares are set at $15.Chardan Capital Markets Initiated Arrowhead Research Corp on May 19, 2016 to “Buy”, Price Target of the shares are set at $12.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.